OBJECTIVES: Analysis of timing, type, electrocardiographic and patient characteristics of postinterventional bradyarrhythmias after CoreValve implantation. BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become an accepted alternative to surgical therapy in patients with high risk. Among the major drawbacks of this procedure is the need for postprocedural permanent pacemaker implantation (PPM). Although predictors for the postinterventional need for PPM are increasingly recognized, thresholds and rates may vary between centers. METHODS: We conducted a retrospective single-center analysis in 130 consecutive patients with successful transfemoral CoreValve implantation without preexisting pacemaker implants. RESULTS: Postprocedural bradyarrhythmias occurred in 36.2% post-TAVI. Compared to those without postinterventional bradyarrhythmias, these patients had longer preprocedural PR intervals (P = 0.012), broader QRS-complexes (P = 0.001) and prolonged QTc intervals (P = 0.001). Patients with postinterventional bradyarrhythmias had significantly more often preprocedural RBBB (35.2 vs. 14.1%; P = 0.0059). In contrast, no difference was observed with respect to annulus/prosthesis ratio or the use of the large 29-mm prosthesis. The vast majority of patients developed bradyarrhythmias directly after CoreValve implantation or within the first 48 h thereafter. However, 7.6% developed significant bradyarrhythmia more than 48 h after TAVI, and 3.8% of the whole cohort developed significant bradyarrhythmias even >96 h after TAVI. One patient died at day 5 post-TAVI due to asystole. CONCLUSIONS: Late occurrence of bradyarrhythmias should be recognized as a significant contributor to postprocedural outcome after TAVI. Although this is a well known phenomenon after surgical valve replacement, it is less recognized after TAVI.
OBJECTIVES: Analysis of timing, type, electrocardiographic and patient characteristics of postinterventional bradyarrhythmias after CoreValve implantation. BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become an accepted alternative to surgical therapy in patients with high risk. Among the major drawbacks of this procedure is the need for postprocedural permanent pacemaker implantation (PPM). Although predictors for the postinterventional need for PPM are increasingly recognized, thresholds and rates may vary between centers. METHODS: We conducted a retrospective single-center analysis in 130 consecutive patients with successful transfemoral CoreValve implantation without preexisting pacemaker implants. RESULTS: Postprocedural bradyarrhythmias occurred in 36.2% post-TAVI. Compared to those without postinterventional bradyarrhythmias, these patients had longer preprocedural PR intervals (P = 0.012), broader QRS-complexes (P = 0.001) and prolonged QTc intervals (P = 0.001). Patients with postinterventional bradyarrhythmias had significantly more often preprocedural RBBB (35.2 vs. 14.1%; P = 0.0059). In contrast, no difference was observed with respect to annulus/prosthesis ratio or the use of the large 29-mm prosthesis. The vast majority of patients developed bradyarrhythmias directly after CoreValve implantation or within the first 48 h thereafter. However, 7.6% developed significant bradyarrhythmia more than 48 h after TAVI, and 3.8% of the whole cohort developed significant bradyarrhythmias even >96 h after TAVI. One patient died at day 5 post-TAVI due to asystole. CONCLUSIONS: Late occurrence of bradyarrhythmias should be recognized as a significant contributor to postprocedural outcome after TAVI. Although this is a well known phenomenon after surgical valve replacement, it is less recognized after TAVI.
Authors: Markus Krane; Marcus-André Deutsch; Sabine Bleiziffer; Lisa Schneider; Hendrik Ruge; Domenico Mazzitelli; Christian Schreiber; Gernod Brockmann; Bernhard Voss; Robert Bauernschmitt; Rüdiger Lange Journal: Am Heart J Date: 2010-09 Impact factor: 4.749
Authors: Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock Journal: N Engl J Med Date: 2010-09-22 Impact factor: 91.245
Authors: Hasan Jilaihawi; Derek Chin; Mariuca Vasa-Nicotera; Mohamed Jeilan; Tomasz Spyt; G Andre Ng; Johan Bence; Elaine Logtens; Jan Kovac Journal: Am Heart J Date: 2009-05 Impact factor: 4.749
Authors: Peter Wenaweser; Thomas Pilgrim; Nadja Roth; Alexander Kadner; Stefan Stortecky; Bindu Kalesan; Fabienne Meuli; Lutz Büllesfeld; Ahmed A Khattab; Christoph Huber; Balthasar Eberle; Gabor Erdös; Bernhard Meier; Peter Jüni; Thierry Carrel; Stephan Windecker Journal: Am Heart J Date: 2011-05-11 Impact factor: 4.749
Authors: Corrado Tamburino; Davide Capodanno; Angelo Ramondo; Anna Sonia Petronio; Federica Ettori; Gennaro Santoro; Silvio Klugmann; Francesco Bedogni; Francesco Maisano; Antonio Marzocchi; Arnaldo Poli; David Antoniucci; Massimo Napodano; Marco De Carlo; Claudia Fiorina; Gian Paolo Ussia Journal: Circulation Date: 2011-01-10 Impact factor: 29.690
Authors: Sabine Bleiziffer; Hendrik Ruge; Jürgen Hörer; Andrea Hutter; Sarah Geisbüsch; Gernot Brockmann; Domenico Mazzitelli; Robert Bauernschmitt; Rüdiger Lange Journal: JACC Cardiovasc Interv Date: 2010-05 Impact factor: 11.195
Authors: Raffi Bekeredjian; Ulrike Krumsdorf; Emanuel Chorianopoulos; Klaus Kallenbach; Mathias Karck; Hugo Albert Katus; Wolfgang Rottbauer Journal: Am J Cardiol Date: 2010-11-04 Impact factor: 2.778
Authors: Marcel Weber; Eva Brüggemann; Robert Schueler; Diana Momcilovic; Jan-Malte Sinning; Alexander Ghanem; Nikos Werner; Eberhard Grube; Wolfgang Schiller; Fritz Mellert; Armin Welz; Georg Nickenig; Christoph Hammerstingl Journal: Clin Res Cardiol Date: 2015-05-13 Impact factor: 5.460
Authors: Anna Kostopoulou; Panagiotis Karyofillis; Efthimios Livanis; George Karavolias; George Theodorakis; John Paraskevaides; Vassilis Voudris Journal: Curr Treat Options Cardiovasc Med Date: 2016-02
Authors: Nicolas A Geis; Emmanuel Chorianopoulos; Klaus Kallenbach; Florian André; Sven T Pleger; Matthias Karck; Hugo A Katus; Raffi Bekeredjian Journal: Clin Res Cardiol Date: 2014-04-21 Impact factor: 5.460